Articles By Matthew Pillar

31. Key Biomanufacturing Ingredient In Short Supply 6/26/2023

    Biopharma supply chains and manufacturing capacity are on the comeback trail, but one of the key requirements for sustainable development and manufacturing success remains elusive. NIIMBL Workforce Director John Balchunas shares perspective from a unique vantage point.

32. Where Oncology Drug Discovery Goes Next 5/30/2023

    AbbVie Bay Area Site Head and VP of Oncology Discovery Research Steve Davidsen, Ph.D. lays out the primary challenges to pushing forward in areas of high, unmet oncological need: accelerating discovery to shorten the time to patient impact and identifying optimal patients for a given mechanism of action or molecule.

33. Immunome's Platform Partnership Potential 5/16/2023

    Immunome’s discovery engine caught AbbVie’s eye, nabbing the biotech a transformative deal. CEO Purnanand Sarma, Ph.D. and CFO Corleen Roche take us behind the scenes.

34. Active ADC Space Challenges Development Strategies 5/15/2023

    Payload and linker technology advances have contributed to an explosion in antibody-drug conjugate development in recent years, amd the funding has followed. But, while the face value of ADC activity represents a bright spot in an otherwise sluggish biotech investment environment, the challenges of doing business in a hotly competitive market are playing out.

35. Anatomy Of A Biopharma VC Deal 4/20/2023

    Why does a venture capitalist choose to fund a biopharma company? What prompts them to choose not to? And why should (or shouldn't) a biopharma company take a VC's money?

36. Topical Biologics In Ophthalmology? 3/21/2023

    A recent clinical study of an eyedrop formulated with Grifols’ Immunoglobulin-based Flebogamma DIF offers cause for optimism among multiple stakeholders. It could become the first-approved topically administered biologic therapy for dry eye disease. 

37. AAV Manufacturing Field: An Interactive Look 3/17/2023

    Mapping the adeno-associated virus (AAV) therapeutic space gives us a glimpse into indication priorities for gene therapy, and a look at whose got their fingers in which partners’ pots. Check out this interactive graphic from DeciBio Principal Carl Schoellhammer, Ph.D. It's not only instructive, its kind of therapeutic to play with. 

38. Cashing In On Biopharma Collaboration 3/14/2023

    How does a biopharma business that’s potentially years away from its first shot at therapeutic sales revenue thrive in a high-inflation, high-interest, supply-constrained business environment?

39. What's In A “Biopharma” Name? 2/23/2023

    As exciting new modalities, hybrids, and conjugates blur therapeutic lines, let’s not forget what “bio” means, how biologic therapeutics are distinguished, and why they were delineated as such in the first place. Make sure you're not a BINO (Bio In Name Only) when you’re naming your “biotech.”

40. FDA Submission Automation: Coming To A Cloud Near You 2/15/2023

    The FDA is laying the groundwork for standardized, cloud-based electronic submission standards via an initiative that leverages data automation and artificial intelligence. What will it mean to biopharma filers?